Table 6. Cox analysis stratified by biological effective dose and primary tumor type.

Shows overall survival of patients by primary site and BED₁₀.

Tumor type	Biological effective dose	N	Multivariable HR (95% CI)	P
Breast cancer	SRS <55 BED10 Gy	38	Ref
	SRS >=55 BED10 Gy	89	0.89 (0.53–1.50)	0.66
	SRT <55 BED10 Gy	43	1.02 (0.58–1.80)	0.95
NSCL	SRS <55 BED10 Gy	1,579	Ref
	SRS >=55 BED10 Gy	2,828	1.01 (0.94–1.08)	0.87
	SRT <55 BED10 Gy	1,109	0.93 (0.85–1.01)	0.09
SCLC	SRS<55 BED10 Gy	66	Ref
	SRS>=55 BED10 Gy	96	1.16 (0.80–1.69)	0.44
	SRT<55 BED10 Gy	33	1.51 (0.92–2.46)	0.10
Other types of lung cancer	SRS<55 BED10 Gy	80	Ref
	SRS>=55 BED10 Gy	79	0.95 (0.66–1.37)	0.78
	SRT<55 BED10 Gy	59	1.32 (0.89–1.20)	0.16
Melanoma	SRS<55 BED10 Gy	130	Ref
	SRS>=55 BED10 Gy	190	0.82 (0.62–1.09)	0.18
	SRT<55 BED10 Gy	120	0.83 (0.61–1.13)	0.24
Kidney cancer	SRS<55 BED10 Gy	70	Ref
	SRS>=55 BED10 Gy	133	0.96 (0.70–1.33)	0.82
	SRT<55 BED10 Gy	42	0.67 (0.43–1.04)	0.07

Notes.

The number of patients with colon cancer is too low to do the subset cox analysis.